Another study found that patients with epithelial ovarian cancer (EOC) and a high co-expression level of SLC7A11 and GPX4 had a 60-fold higher risk of developing platinum resistance compared with patients with a low level of co-expression. The gene discussed is SLC7A11; the disease is ovarian carcinoma.